Viewing

STEM Series Part 2: A Success Story of a Young Singaporean Scientist

In Part 2 of our STEM Series on how CSI Singapore supports the pursuit of STEM related courses and careers, we feature our very own CSI Singapore Principal Investigator, Dr Tam Wai Leong. Dr Tam is a young and promising Singaporean scientist who was educated and trained in Singapore. He was recently featured in The

Comprehensive Mutational Analysis of Primary and Relapse Acute Promyelocytic Leukemia. (Leukemia, Apr 2016)

Madan V1, Shyamsunder P1, Han L1,2, Mayakonda A1, Nagata Y3, Sundaresan J1, Kanojia D1, Yoshida K3, Ganesan S4, Hattori N1, Fulton N5, Tan KT1, Alpermann T6, Kuo MC7, Rostami S8, Matthews J9, Sanada M3, Liu LZ1, Shiraishi Y10, Miyano S10, Chendamarai E4, Hou HA11, Malnassy G5, Ma T12, Garg M1, Ding LW1, Sun QY1, Chien

Inaugural BOCA Pow-wow Meeting in 2016

The BOCA (Breast and Ovarian Cancers) Pow-wow sessions is among the many journal clubs that CSI Singapore organizes. It started in 2015 with the objective of promoting knowledge and camaraderie among the staff and students working on breast and ovarian cancers. The aim is to consolidate the vast array of experience from different individuals working

8th HOPE Meeting with Nobel Laureates Inspires CSI PhD Student

The 8th HOPE Meeting with Nobel Laureates was held in Tsukuba, Japan on 7 - 11 March 2016. Eve Wang Chao, PhD Student from CSI Singapore (Dr Alan Prem Kumar's group), was privileged to be selected to attend this meeting and given the exceptional opportunity to learn from a lineup of distinguished Nobel Laureates. The

Acquired Resistance to Combination Treatment through Loss of Synergy with MEK and PI3K Inhibitors in Colorectal Cancer. (Oncotarget, Apr 2016)

Bhattacharya B1, Hui Low SH1, Chong ML1, Chia D2, Koh KX3, Sapari NS1, Kaye S4, Hung H5, Benoukraf T1, Soong R1,3 1Cancer Science Institute of Singapore, National University of Singapore, Singapore. 2Department of Pharmacy, National University of Singapore, Singapore. 3Department of Pathology, National University of Singapore, Singapore. 4Drug Development Unit, Royal Marsden NHS Trust, The

Next-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer. (Lung Cancer, Mar 2016)

Tan CS1, Cho BC2, Soo RA3 1Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore. 2Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea. 3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; School

Anticancer Properties of Nimbolide and Pharmacokinetic Considerations to Accelerate its Development. (Oncotarget, Mar 2016)

Wang L1,2, Phan DD1,3, Zhang J2, Ong PS3, Thuya WL1,3, Soo RA1,4, Wong AL1,4, Yong WP1,4, Lee SC1,4, Ho PC3, Sethi G2, Goh BC1,2,4 1Cancer Science Institute of Singapore, National University of Singapore, Singapore. 2Department of Pharmacology, National University Health System, Singapore. 3Department of Pharmacy, National University of Singapore, Singapore. 4Department of Haematology-Oncology, National University